SCHEMBL22493739

SCHEMBL22493739

CC(C)(C)NCCc1cccc(-c2ccncc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 3/20 0.49
TRPV3 Q8NET8 8/20 0.39
LATS1 O95835 1/20 0.35
LATS2 Q9NRM7 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
KCNH2 Q12809 1/20 0.35
NPC1 O15118 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
AR P10275 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22480758 0.85 TRPV3 (0.39) PDE10ATRPV3KDM4ECTSLCTSB
SCHEMBL22493434 0.85 CYP2A6 (0.50) PDE10ATRPV3KDM4EGAANPC1
SCHEMBL22493894 0.84 SCN9A (0.44) TRPV3CTSLCTSBCTSSCTSK
SCHEMBL22493866 0.84 CNR2 (0.39) PDE10ATRPV3KDM4ECTSLCTSB
SCHEMBL22480829 0.80 TRPV3 (0.43) TRPV3KDM4ECTSLCTSBCTSS
SCHEMBL22493470 0.79 CNR2 (0.44) TRPV3CTSLCTSBCTSSCTSK
SCHEMBL22493472 0.79 TRPV3 (0.43) TRPV3KDM4ECTSLCTSBCTSS
SCHEMBL23541648 0.77 IRAK4 (0.41) PDE10A
SCHEMBL22493432 0.75 GRM2 (0.36) KDM4ECTSLCTSBCTSSCTSK
SCHEMBL17886911 0.74 SMN1; SMN2 (0.46) CTSLCTSBCTSSCTSKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137506-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. (US) 2024-06-27 WO disclosed
WO-2023225021-A1 COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) CURASEN THERAPEUTICS, INC. (US) 2023-11-23 WO disclosed
WO-2020198466-A9 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed
WO-2020198466-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-10-01 WO disclosed